Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.78
+4.1%
$1.22
$1.78
$40.66
$53.67M1.4620,672 shs370,847 shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$14.46
-5.8%
$14.29
$10.57
$33.33
$2.10B1.331.14 million shs1.10 million shs
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.87
-6.4%
$1.95
$0.91
$6.05
$240.16M2.152.64 million shs1.93 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.15
-1.3%
$1.20
$0.66
$5.92
$132.36M2.182.22 million shs777,948 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.62
-4.9%
$8.94
$5.04
$15.36
$433.38M1.06927,868 shs177,105 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cortexyme, Inc. stock logo
CRTX
Cortexyme
+6.21%+6.87%+46.15%+69.31%+137.50%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
+2.33%+4.46%+0.59%+20.87%-29.10%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-0.65%+18.38%+45.71%+135.38%-39.76%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
+0.87%+1.31%-30.54%+9.43%-62.82%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-1.20%+3.78%-7.65%+53.82%-15.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.7216 of 5 stars
4.52.00.04.73.82.50.0
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.0681 of 5 stars
3.23.00.04.31.12.50.6
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.288 of 5 stars
3.13.00.04.73.21.70.6
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
4.4083 of 5 stars
3.43.00.04.61.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.06
Buy$33.71133.16% Upside
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.31
Hold$4.7064.05% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.13
Hold$3.83234.79% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$31.63266.88% Upside

Current Analyst Ratings Breakdown

Latest DNLI, FATE, RGNX, CRTX, and EDIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/9/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00
5/19/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.00
5/8/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $32.00
4/29/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.36N/AN/A$8.53 per share1.70
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M7.42N/AN/A$1.63 per share1.76
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.63M9.63N/AN/A$2.80 per share0.41
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$83.33M5.19N/AN/A$5.24 per share1.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)

Latest DNLI, FATE, RGNX, CRTX, and EDIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.73N/AN/AN/AN/AN/A
8/7/2025Q2 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.13N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.40N/AN/AN/A$1.81 millionN/A
5/13/2025Q1 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million
5/12/2025Q1 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
5/6/2025Q1 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.56
9.56
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
3.08
3.08
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.81
8.81
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.93
2.93

Institutional Ownership

CompanyInstitutional Ownership
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%

Insider Ownership

CompanyInsider Ownership
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.10%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5.51%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.28 million127.12 millionOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23083.71 million81.96 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.29 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.16 million43.75 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.78 +0.07 (+4.09%)
As of 07/10/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$14.44 -0.91 (-5.90%)
As of 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.86 -0.20 (-6.37%)
As of 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$1.14 -0.02 (-1.29%)
As of 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$8.64 -0.42 (-4.67%)
As of 03:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.